M4MM

Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...

Curaleaf Raises Bid to Acquire Aurora Cannabis

STAMFORD – Curaleaf Holdings Inc. announced it will file a notice to increase its acquisition offer for Aurora Cannabis Inc. to US$5.00 per share. Under the enhanced terms, Aurora shareholders would receive 0.4013 Curaleaf shares ...

Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...

Q2 2026: The Quarter That Counted For Psychedelics

LOS ANGELES – Q2 2026 gave the psychedelic medicine sector the quarter that practitioners, investors, and regulators had been building up for years. Clinical programs delivered Phase 3 results, the White House signed an executive ...

Subscribe To Our Newsletter